Skip to main content

Articles Tagged With:

  • CTU Updates

    Enter abstracts for ARHP annual conference; New payment options announced for Mirena
  • Hormone therapy: Make decisions on a balanced risk-to-benefit basis

    Family planning clinicians have found their care of postmenopausal women has changed dramatically since the July 2002 cessation of the estrogen/progestin arm of the Womens Health Initiative (WHI). The estrogen/progestin arm of the landmark study was halted after findings showed that the overall health risk, particularly of cardiovascular disease and breast cancer, from taking estrogens with progestin was greater than the benefits of lowering the risk of colon cancer and bone fractures.
  • Use the web for hormone therapy information

    Check out the following Internet resources for more information on hormone therapy.
  • Getting men on board: one facility’s approach

    If the number of men on your patient rosters is low, take a look at the approach used by Planned Parenthood of San Antonio and South Central Texas. In the first year of its marketing initiative, the number of its male patients nearly doubled from 2% to 3.7% of total patients served.
  • Full April 1, 2003 Issue in PDF

  • Aneurysms and atypical pain can impede correct diagnosis

    This issue of ED Legal Letter is the second of a four-part series related to pitfalls associated with evaluating patients with abdominal pain. The series will analyze high-risk and life-threatening disease processes that ED physicians will encounter in their daily practice. Part two explores gastrointestinal (GI) bleeding and the necessity of Hemoccult testing; the diagnosis and treatment of aortic aneurysms and abdominal trauma; and extra-abdominal causes of abdominal pain.
  • Full March 1, 2003 Issue in PDF

  • Norovirus Infection

    Noroviruses are a frequent cause of acute gastroenteritis. During the last 2 months of 2002 in a single health district in Washington state, 10 outbreaks of acute gastroenteritis attributable to norovirus were investigated. These events affected 354 patients in 6 long-term care facilities, a community hospital, an outpatient clinic, and the county jail.
  • Vancomycin TDM: Therapeutic Drug Monitoring or Just Fooling Ourselves?

    Despite many years of practice, a recent questionnaire about therapeutic drug monitoring of vancomycin revealed marked variability and a lack of consensus regarding postdose assay sampling times, target ranges, and what constituted a toxic level.
  • Updates

    KS Fails to Respond to Cidofovir; Acyclovir & Renal Dysfunction; Broad-Range Bacterial PCR in Meningitis; Why is BCG Less Virulent than MTb?.